1. Why Opioid Withdrawal Syndrome Should Be on Your Radar

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Overview of Presentation

4. Opioids Change the Way Brain Cells Function, Leading to Withdrawal at Discontinuation

5. Opioids Change the Way Brain Cells Function, Leading to Withdrawal at Discontinuation (cont)

6. Opioids Change the Way Brain Cells Function, Leading to Withdrawal at Discontinuation (cont)

7. Opioids Change the Way Brain Cells Function, Leading to Withdrawal at Discontinuation (cont)

8. μ-Opiate Receptor Coupling to cAMP Second Messenger

9. Morphine Inhibition of cAMP Formation

10. Up-Regulation Due to μ-Opiate Receptor Inhibition of cAMP Formation

11. Convergence of the α2-Adrenergic and µ-Opiate Receptor Signaling Pathways

12. Central α2-Adrenergic Agonist

13. What Is OWS?

14. Time Course of OWS for Short-Acting Opioids

15. OWS From a Personal Perspective

16. Withdrawal Management Critical for Successful Transition to Post-Withdrawal Treatment

17. Importance of Withdrawal Management

18. Current Standard of Care for Withdrawal Management

19. Buprenorphine

20. Opioid Withdrawal Severity at Equivalent Doses

21. Abruptly Stopping Methadone at 35 mg Daily

22. Lofexidine Addresses Unmet Need in Opioid Withdrawal Management

23. Patient Risks With Lofexidine

24. SOWS-Gossop

25. Randomized Double-Blind Study of Lofexidine vs Placebo Median Time to Dropout

26. Randomized Double-Blind Study of Lofexidine vs Placebo Mean SOWS-Gossop Score

27. Optimizing Patient Risks and Benefits With the Use of Lofexidine

28. Comprehensive Risk-Benefit Analysis

29. Patient Selection Considerations

30. Lofexidine Dosing Information

31. Abbreviations